Latest Administration News

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

Aspen Group has launched a $4 million Security Purchase Plan (SPP) at $2.90 per security, offering eligible investors a chance to buy new stapled securities without brokerage fees. This move follows a recent $70 million institutional placement aimed at strengthening the balance sheet for future acquisitions.

Prescient Therapeutics has reached a pivotal milestone by dosing the first patient in its Phase 2a clinical trial of PTX-100 for relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), aiming to evaluate safety and efficacy across multiple international sites.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Nufarm Limited confirms its half-year earnings align closely with analyst expectations despite a late-stage $16 million inventory valuation adjustment. The company maintains compliance with ASX disclosure rules amid market scrutiny.

Jameson Resources has raised A$3.5 million through a two-tranche placement to fund environmental approvals and Indigenous engagement for its Crown Mountain Hard Coking Coal Project in Canada.

4DMedical has submitted its CT:VQ™ software to the FDA, aiming to revolutionize lung ventilation and perfusion imaging by replacing traditional nuclear scans with a non-contrast CT-based solution.

Alma Metals has announced a pro-rata non-renounceable rights offer to raise approximately $1.06 million, aiming to fund critical drilling and a scoping study at its Briggs Copper Project in Queensland.

Macarthur Minerals Limited has launched a pro-rata entitlement offer to raise nearly $2 million, issuing new shares with free attaching options, fully underwritten by Gold Valley Yilgarn Pty Ltd. The capital raise aims to advance exploration and development at its Giles Lake Iron Project and support corporate operations.